EP2/EP4 activation was shown to correlate with induction of urothelial cancer initiation and outgrowth, as well as bladder cancer progression and resistance to cisplatin, presumably via downregulating PTEN expression [45]. The gene discussed is PTEN; the disease is urinary bladder cancer.